IL-17i

DRUG2 trials

Sponsors

Janssen Pharmaceutica N.V., Belgium, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Conditions

Arthritis, PsoriaticEnthesitisPsoriasis (PsO)Psoriasis ArthritisSecukinumab

Unknown Phase

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

Active, not recruitingNCT05049798

Janssen Pharmaceutica N.V., BelgiumArthritis, Psoriatic

Start: 2021-08-25End: 2027-08-02Updated: 2026-08-28

A Prospective Study to Assess the Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Severe Psoriasis Based on Power Doppler (PD) Ultrasonography (PDUS)

RecruitingNCT06987292

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolEnthesitis, Psoriasis Arthritis, Psoriasis (PsO) +1

Start: 2025-05-01End: 2027-12-31Target: 50Updated: 2025-05-23

Related Papers

Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study

The Journal of Rheumatology2026-08-01

Persistence and Effectiveness Across PsA Patient Subgroups with Guselkumab and IL-17 Inhibitors: 6-Month Results of the Psabiond Observational Study

The Journal of Rheumatology2026-08-01

Guselkumab and Il-17 Inhibitors Improve Patient-Perceived Impact of Psoriatic Arthritis Similarly: 6 Month Interim Results of the PsABIOnd Observational Cohort Study

The Journal of Rheumatology2025-07-01

P167 Guselkumab and IL-17 inhibitors show comparable treatment persistence and effectiveness in psoriatic arthritis outcomes: 6-month interim results of the PsABIOnd observational cohort study

Lara D. Veeken2025-04-01

E090 Guselkumab and IL-17 inhibitors improve patient-perceived impact of psoriatic arthritis similarly: 6-month interim results of the PsABIOnd observational cohort study

Lara D. Veeken2025-04-01

PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis.

2022-12-305 citations